CSIMarket Company Name, Ticker, Industry, else..
 
Pasithea Therapeutics Corp   (NASDAQ: KTTA)
 
Price: $0.5322 $-0.01 -1.444%
Day's High: $0.5515000224113464 Week Perf: -8.24 %
Day's Low: $ 0.52 30 Day Perf: 8.61 %
Volume (M): 28,971 52 Wk High: $ 2.06
Volume (M$): $ 0 52 Wk Avg: $0.74
Open: $0.54 52 Wk Low: $0.28



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 32
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Business Description


Pasithea Therapeutics Corp is a pharmaceutical company that focuses on developing novel therapeutics for the treatment of sleep disorders and mental health conditions. The company aims to improve patient outcomes and quality of life by addressing unmet needs in these areas. With a combination of innovative science and cutting-edge technology, Pasithea Therapeutics Corp is dedicated to advancing the field of sleep and mental health therapeutics.


   Company Address: 1111 Lincoln Road Miami Beach 33139 FL
   Company Phone Number: 977-3380   Stock Exchange / Ticker: NASDAQ KTTA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALZN        1.76% 
ANRO   -12.91%    
ATAI      0% 
CMPS        7.9% 
ENVB        1.39% 
NRXP   -0.44%    
• View Complete Report
   



Clinical Study

Pasithea Therapeutics Expands Clinical Trials for NF1 Treatment to South Korea Despite Financial Challenges

Published Tue, Sep 16 2025 12:14 PM UTC

: Pasithea Therapeutics Corp. (Nasdaq: KTTA) has recently made significant strides in its clinical research initiatives by activating clinical trial sites in South Korea for its Phase 1/1b study of PAS-004, aimed at treating adult patients with Neurofibromatosis Type 1 (NF1). This development marks an important step in addressing the needs of patients suffering from this chr...
Clinical Study

Promising Safety Advances in Pasithea Therapeutics Phase 1 Trial of PAS-004 for Advanced Cancer,

Published Wed, Nov 20 2024 12:02 PM UTC

Pasithea Therapeutics PAS-004 Phase 1 Trial Shows Promising Safety Profile in Advanced Cancer Treatment Pasithea Therapeutics, a nascent player in the biopharmaceutical field, has become a focal point of industry attention with its ongoing Phase 1 clinical trial of PAS-004, targeted at treating advanced cancers with specific genetic mutations such as RAS, NF1, and RAF. Key ...
Product Service News

Promising Phase 1 Results for PAS-004 A Potential New Treatment for Advanced Cancer

Published Thu, Sep 26 2024 11:02 AM UTC

Pasithea Therapeutics has released initial results from its Phase 1 clinical trial for PAS-004, a novel therapeutic candidate aimed at treating advanced cancers, particularly those associated with neurofibromatosis type 1 (NF1) and MAPK pathway alterations. The findings indicate promising safety, tolerability, and preliminary efficacy outcomes, marking a significant step ...
Clinical Study

Balancing Hope and Reality Pasithea Therapeutics’ Journey with PAS-004 in the Landscape of Chronic Toxicity and Fin...

Published Mon, Sep 9 2024 12:01 PM UTC

In the rapidly evolving world of biotech, where breakthroughs can happen overnight but financial challenges loom ominously, Pasithea Therapeutics finds itself at a pivotal crossroads. Recently, the company announced the successful completion of its chronic toxicity studies for PAS-004, a promising investigational treatment aimed at addressing the complex needs of patients wi...
Management Announcement

Pasithea Therapeutics Appoints Dr. Rebecca Brown to Scientific Advisory Board and Completes Successful Tender Offer Acquisition, Building Investor Confidence and Enhancing Growth Potential,

Published Tue, Sep 3 2024 12:02 PM UTC


Pasithea Therapeutics, a leading biotech company, has recently appointed Dr. Rebecca Brown to its Scientific Advisory Board. Dr. Brown, an expert in Neurofibromatosis and Director at Mount Sinai, will be instrumental in providing her expertise to aid in the development of PAS-004. This appointment highlights Pasithea Therapeutics commitment to advancing medical researc...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 11.08
Price to Sales (Expected) -
Price to Book 0.34
PEG (TTM) -

Financial Strength Current
Quick Ratio 49.76
Working Capital Ratio 51.1
Leverage Ratio (MRQ) 0.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.38 $
Revenues (TTM) 0.05 $
Cash Flow (TTM) -
Cash 2.85 $
Book Value 1.55 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,394,078
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.